HUTCHMED’s IMG-007 and IMG-004 are licensed by Inmagene as “options to license” under the terms of the agreement signed in Jan 2021. Inmagene will further develop, manufacture and commercialize the drugs
As per the terms, HUTCHMED, for each of its drugs, will obtain ~$92.5M milestones for their development and ~$135M on achieving commercial milestones plus royalties associated with commercialization
Additionally, Inmagene has commenced two P-IIa studies evaluating IMG-007 for treating adults with moderate-to-severe atopic dermatitis and alopecia areata. It also concluded P-I single ascending dose (SAD) trial for immunological diseases
Ref: HUTCHMED | Image: Inmagene
Related News:- Chi-Med and Inmagene Collaborate to Develop Therapies for Immunological Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
